Q4 2025 Merck KGaA Earnings Call Transcript
Key Points
- Merck KGaA (MKGAF) delivered solid organic net sales growth and EBITDA growth despite challenging macro and geopolitical environments.
- The Life Science business returned to organic growth, driven by a 10% increase in the process solutions segment.
- Healthcare posted a 3% organic sales growth, with the newly established rare disease business contributing 5% points of inorganic growth.
- Electronics showed strong performance in semiconductor materials, supported by AI-driven demand.
- Merck KGaA (MKGAF) achieved a 60% reduction in scope 1 and 2 greenhouse gas emissions, surpassing their 2025 target.
- Net sales declined by 3.1% in Q4, impacted by FX headwinds, particularly from the US dollar and various Asian currencies.
- Electronics experienced a 2% organic decline in Q4 due to challenges in delivery systems and services.
- Healthcare faced life cycle challenges for key brands, particularly Mavenclad, with anticipated sales declines.
- The company expects Q1 2026 to be at the lower end of guidance due to various factors, including FX headwinds and tough comparisons.
- There is uncertainty regarding the timing and approval of Pergovaris in the US, affecting potential sales forecasts.
Mm.
Dear ladies and gentlemen, welcome to the Merck Investor and Analyst Conference call on 4th quarter and full year 2025.
As a reminder, all participants will be in a listen-only mode.
I'm now handing over to Florian Schrader, head of investor relations, who will lead you through this conference. Please go ahead, sir.
Thank you very much, Sarah, and a sincere welcome to everyone joining us for the Q4 and full year 25 earnings call.
My name is Florian Schroeder, and I'm the head of investor relations at Merck.
I am delighted to be joined by Belen Garrejo, group CEO, Helena von Reeder, Group CFO, as well as Kai Beckmann, Deputy Chairman of the executive Board.
For the Q&A part of the call, we will be further joined by Jean-C Charles Dier, CEO of Life Science, and Dennis Barzohar, CEO of Healthcare.
As you have surely noticed, we recently announced upcoming changes to the executive board. I am pleased to share that Benjamin Hein,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
